ClotCare: Blood Clots, Stroke, Heart Attack
Monday, May 27, 2024
Home   |   DVT/PE   |   Blood Clots   |   Coumadin/Warfarin   |   New Patients   |   Self Testing   |   Email List   |   Donate

Pick a Topic:

Find info on a:

We subscribe to the HONcode principles of the HON Foundation. Click to verify.
ClotCare complies with the HONcode standard for trustworthy health
verify here.

ClotCare is a member of the Coalition to Prevent Deep Vein Thrombosis (DVT Coalition)  ClotCare is a member organization of the Coalition to Prevent Deep Vein Thrombosis. Click here to learn more about the Coalition to Prevent Deep Vein Thrombosis and DVT Awareness Month, which is held each March.

Controversy Surrounds FDA Panel's Unanimous Vote to Approve New Antiplatelet Agent Prasugrel

Henry I. Bussey, Pharm.D.
February, 2009

According to, the FDA panel voted to recommend approval of prasugrel, a clopidogrel-like drug, but concerns persist about the bleeding risk and a possible carcinogenic potential. Because of an increased bleeding risk, there was concern that use should be limited or the dose reduced in patients weighing 60 kg of less and/or those 75 years of age and older. It also may be contraindicated in patients with a history of stroke or transient ischemic attack. Finally, the concern about cancer deaths stems from findings in the TRITON-TIMI-38 study in which there were 33 deaths in the prasugrel group and 21 in the clopidogrel group; some consider this a spurious finding.

The panel's vote was unanimous, but the makeup of the panel has raised concern in the medical field. Specifically, in a very controversial move, Dr. Sanjay Kaul was excluded from the FDA advisory panel. Dr. Kaul is a vascular physiology expert at Cedars-Sinai Medical Center in Los Angeles, CA and has been openly critical of prasugrel. Many in the industry are asking why he was excluded from the panel and are suggesting that the panel was "designed" to approve this drug. The links below include more information on the controversy:

  1. Red flags raised over FDA advisory-panel hearing on prasugrel

  2. "Mistakes" made: FDA acknowledges Lilly phoned to question Sanjay Kaul's inclusion on prasugrel panel

Note that this story is reporting the action of an FDA PANEL; this is NOT the final FDA approval. The panel votes to recommend a particular action to the FDA, and the FDA usually - but not always - follows the recommendation of the panel. So this action probably will result in FDA approval, but it does not assure FDA approval.

Ask a question about blood clots or anticoagulant medications Have questions? Ask ClotCare. Send questions by email to

ClotCare is a 501(c)(3) non-profit organization generously supported by your tax-deductible donations and grants from our industry supporters.

Blood Clot Activities Calendar

New Postings:

Click here to view full list of new postings
ClotCare Home | New Postings | Patient Postings | Clinician Postings | Join Our Email List | Useful Web Links
CE Opportunities | Training Programs | DVT & PE Stories | Editorial Board | Financial Support
About ClotCare | DVT Coalition | Donate to ClotCare | Contact Us
Key topics discussed on ClotCare include: Blood Clots | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE) | Atrial Fibrillation (A. Fib or AF) | Heart Attack | Stroke | Transient Ischemic Attack (TIA) | Mini Stroke | Bleeding Complications | Vascular Surgery | Surgical Blood Clot Removal | Warfarin | Coumadin | Lovenox | Low Molecular Weight Heparin (LMWH) | Heparin | Anticoagulants | Plavix | Aspirin | Antiplatelets | Blood Thinners
Copyright 2000-2018 by ClotCare. All rights reserved.
Terms, Conditions, & Privacy | Image Copyright Information
19260 Stone Oak Parkway, Suite 101 | San Antonio, TX 78258 | 210-860-0487
Send comments to
Monday, May 27, 2024